Stephanie T. Schmidt, PhD, on Neoadjuvant Chemotherapy and Immune-Based Treatments in NSCLC

Stephanie T. Schmidt, PhD, of The University of Texas MD Anderson Cancer Center, discusses the concept of immunomics, how it is used to examine the effects of neoadjuvant chemotherapy and immune-based treatments in patients with non–small cell lung cancer, and the clinical implications of her findings for treatment selection or patient eligibility for a variety of therapies.